Quality by design approach for viral clearance by protein a chromatography

Protein A chromatography is widely used as a capture step in monoclonal antibody (mAb) purification processes. Antibodies and Fc fusion proteins can be efficiently purified from the majority of other complex components in harvested cell culture fluid (HCCF). Protein A chromatography is also capable of removing modest levels of viruses and is often validated for viral clearance. Historical data mining of Genentech and FDA/CDER databases systematically evaluated the removal of model viruses by Protein A chromatography. First, we found that for each model virus, removal by Protein A chromatography varies significantly across mAbs, while remains consistent within a specific mAb product, even across the acceptable ranges of the process parameters. In addition, our analysis revealed a correlation between retrovirus and parvovirus removal, with retrovirus data generally possessing a greater clearance factor. Finally, we describe a multivariate approach used to evaluate process parameter impacts on viral clearance, based on the levels of retrovirus‐like particles (RVLP) present among process characterization study samples. It was shown that RVLP removal by Protein A is robust, that is, parameter effects were not observed across the ranges tested. Robustness of RVLP removal by Protein A also correlates with that for other model viruses such as X‐MuLV, MMV, and SV40. The data supports that evaluating RVLP removal using process characterization study samples can establish multivariate acceptable ranges for virus removal by the protein A step for QbD. By measuring RVLP instead of a model retrovirus, it may alleviate some of the technical and economic challenges associated with performing large, design‐of‐experiment (DoE)—type virus spiking studies. This approach could also serve to provide useful insight when designing strategies to ensure viral safety in the manufacturing of a biopharmaceutical product. Biotechnol. Bioeng. 2014;111: 95–103. © 2013 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.

[1]  Chintan Dalwadi,et al.  Implementation of "Quality by Design (QbD)" Approach for the Development of 5-Fluorouracil Loaded Thermosensitive Hydrogel. , 2016, Current drug delivery.

[2]  V. Sisodiya,et al.  Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography. , 2012, Biotechnology journal.

[3]  Anurag Rathore Implementation of Quality by Design (QbD) for Biopharmaceutical Products. , 2010, PDA journal of pharmaceutical science and technology.

[4]  R. Bayer,et al.  Recovery and purification process development for monoclonal antibody production , 2010, mAbs.

[5]  S. Lute,et al.  Analysis of viral clearance unit operations for monoclonal antibodies , 2010, Biotechnology and bioengineering.

[6]  K. Brorson,et al.  Proceedings of the 2009 Viral Clearance Symposium. , 2010, Developments in biologicals.

[7]  S. Lute,et al.  Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[8]  Kurt Brorson,et al.  A Novel, Q‐PCR Based Approach to Measuring Endogenous Retroviral Clearance by Capture Protein A Chromatography , 2009, Biotechnology and bioengineering.

[9]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[10]  Anurag S. Rathore,et al.  Quality by design for biopharmaceuticals : principles and case studies , 2009 .

[11]  Kurt Brorson,et al.  Robustness of virus removal by protein A chromatography is independent of media lifetime. , 2008, Journal of chromatography. A.

[12]  A. Rathore,et al.  PDA workshop on "Quality by Design for Biopharmaceuticals: Concepts and Implementation", May 21-22, 2007, Bethesda, Maryland. , 2008, PDA journal of pharmaceutical science and technology.

[13]  Brian Hubbard,et al.  Downstream processing of monoclonal antibodies--application of platform approaches. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  Sanchayita Ghose,et al.  Binding capacity differences for antibodies and Fc‐fusion proteins on protein A chromatographic materials , 2007, Biotechnology and bioengineering.

[15]  Sanchayita Ghose,et al.  Protein A Affinity Chromatography for Capture and Purification of Monoclonal Antibodies and Fc-Fusion Proteins: Practical Considerations for Process Development , 2006 .

[16]  S. Lute,et al.  Normal‐flow virus filtration: detection and assessment of the endpoint in bioprocessing , 2005, Biotechnology and applied biochemistry.

[17]  Liming Shi,et al.  Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification , 2004, Biotechnology and bioengineering.

[18]  Alois Jungbauer,et al.  Engineering protein A affinity chromatography. , 2004, Current opinion in drug discovery & development.

[19]  Alois Jungbauer,et al.  Comparison of protein A affinity sorbents. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  Kurt Brorson,et al.  Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. , 2003, Biotechnology and bioengineering.

[21]  K. Brorson,et al.  Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. , 2003, Journal of chromatography. A.

[22]  J. Vennari,et al.  Detection of minute virus of mice using real time quantitative PCR in assessment of virus clearance during the purification of Mammalian cell substrate derived biotherapeutics. , 2002, Biologicals : journal of the International Association of Biological Standardization.

[23]  Kurt Brorson,et al.  Impact of cell culture process changes on endogenous retrovirus expression. , 2002, Biotechnology and bioengineering.

[24]  M Vanderlaan,et al.  Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes , 2001, Biotechnology & genetic engineering reviews.

[25]  C. Fautz,et al.  Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. , 2000, Biologicals : journal of the International Association of Biological Standardization.

[26]  M Vanderlaan,et al.  Performance comparison of Protein A affinity‐chromatography sorbents for purifying recombinant monoclonal antibodies , 1999, Biotechnology and applied biochemistry.

[27]  Y. Xu,et al.  A real time quantitative PCR-based method for the detection and quantification of simian virus 40. , 1999, Biologicals : journal of the International Association of Biological Standardization.